tbuckley/cabot-search huggingface dataset:
Keeping Faith With Patients After Stroke or Transient Ischemic Attack
Authors: Walter N. Kernan
Journal: JAMA Neurology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Abstract 16488: ERK is Invovled in Neuroprotection of Win55,212-2 Pharmacological Hypothermia After CPR in a Rat Cardiac Arrest Model
Authors: Feng-Qing Song, Tao Yu, Xiangshao Fang, Guanghui Zheng, Longyuan Jiang, Zitong Huang, Yanfang Zuo, Zhengfei Yang
Journal: Circulation (2016)

ERK is involved in the neuroprotection of Win55,212-2 pharmacological hypothermia after CPR in a rat cardiac arrest model  This study was supported by National Natural Science Foundation of China (No.81201447, 81460289)   Introduction:  Studies have demonstrated that Win55,212-2 induced pharmacological hypothermia and improved the outcome of CPR. However, the mechanism is still unclear.   Hypothesis:  In this study, we hypothesize extracellular signal-regulated kinase (ERK) will take part in the neuroprotection of WIN55,212-2 pharmacological hypothermia after CPR in a rat cardiac arrest (CA) model.   Methods:  CA was induced by transoesophageal ventricular pacing in SD rats. 5min after onset of CA, CPR was started. At 5 min post-resuscitation, 30 animals were randomized into 3 groups (n=10 in each group): (1) Win55, 212-2 group; (2) Normothermia group; (3) Win55, 212-2 + ERK blocker PD98059. Animals received PD98059 (3mg/kg) or placebo. After 30 min of ROSC, animals in drug groups were received continuous intravenous infusion of Win55,212-2 (1 mg/kg/h ) for 4 h while which in normothermia group were received 5% DMSO. Rats in normothermia group were maintained at 37°C with warming lamp though the whole experiment. Rats in drug group were warmed to 37°C increasingly after 4h of Win55,212-2 treatment. The survival time and neurological deficit score (NDS) were observed.   Results:  Temperatures of rats in Win55,212-2 group decreased from 37°C to 34°C in 4 hours, which could not be blocked by ERK blocker PD98059. Accumulate survival rate was higher and NDS was significantly improved in Win55 group than those of the normothermia group (P   Conclusions:  Win55, 212-2 inducing pharmacologically hypothermia prolonged survival and improved cerebral function in a rat cardiac arrest model. The beneficial effects of WIN55, 212-2 were associated with ERK signal pathway.
Use of low-dose, weekly carboplatin in men with metastatic castrate-resistant prostate cancer (mCRPC).
Authors: Meghan O'Leary-Kelly, Dexiang Gao, Sarah Weisdack, Elaine Tat Lam, Brandon David Bernard, Thomas W. Flaig, Elizabeth Riley Kessler
Journal: Journal of Clinical Oncology (2018)

331 Background: Medical treatment options for advanced prostate cancer have evolved rapidly in recent years, with multiple new agents available. Our group had previously reported the use of weekly carboplatin for mCRPC in the pre-docetaxel era. The efficacy and toxicities of low-dose, weekly carboplatin were evaluated in a more contemporary patient cohort. Methods: We performed a retrospective review of patients with mCRPC treated with carboplatin from 2006-17 at a single health system. Carboplatin (AUC 2) was given weekly for 4 weeks of a 6-week cycle in combination with 1mg daily dexamethasone. Results: Sixty-four carboplatin-treated patients were identified, with a mean baseline prostate-specific antigen (PSA) of 568.55 ng/mL (range 0.02-4322). The median number of treatment cycles was 3 (range 1-10). The therapy was generally well tolerated and a dose-reduction was required for only 4 patients. Previous therapy included: docetaxel 95.3%, cabazitaxel 21.9%, abiraterone 53.1%, and enzalutamide 29.7%. A PSA decline of 30% occurred in 20 of 64 patients (31%). The response rate varied based on prior therapy. The most common adverse events were fatigue (80%), anemia (64%), and neuropathy (48%). There were 20 patients with Grade 3 adverse events. The most common was thrombocytopenia (n = 9), and 1 grade 4 thrombocytopenia. No other grade 4 toxicities were noted. Conclusions: New treatment options are needed for mCRPC after progression on currently approved agents. Platinum therapy may have increased activity in specific genomic subtypes of prostate cancer. These results compare favorably with the TROPC study of cabazitaxel (39% PSA response) in spite of the heavy pretreatment of our population. This retrospective report shows that carboplatin has activity and little toxicity in an unselected cohort of mCRPC.
I have recently been shortlisted for two different jobs and the interviews take place in the same week. If I am successful in the first job before knowing the outcome of the second, how long can I delay the answer as my preferred job is the second one?
Authors: Sabina Dosani
Journal: BMJ (2006)

Have a career or related problem that needs answering? Can9t find the right person to point you in the right direction? Log on to the Advice Zone for reliable medical careers advice. You can post a question or see if one of our 300 advisers has already answered a similar question. Here is a selection of questions and answers posted on the site. <b>www.bmjcareers.com/advicezone</b>
Effectiveness of a community-based educational programme in reducing the cumulative incidence and prevalence of human Taenia solium cysticercosis in Burkina Faso in 2011–14 (EFECAB): a cluster-randomised controlled trial
Authors: Hélène Carabin, Athanase Millogo, Helena A Ngowi, Cici Bauer, Veronique Dermauw, Assana Cissé Koné, Ida Sahlu, Alicia L Salvator, Pierre-Marie Preux, Télesphore Somé, Zékiba Tarnagda, Sarah Gabriël, Rabiou Cissé, Jean-Bosco Ouédraogo, Linda D Cowan, Marie-Paule Boncoeur-Martel, Pierre Dorny, Rasmané Ganaba
Journal: The Lancet Global Health (2018)

The effectiveness of drug-free interventions in controlling human cysticercosis is not well known. We aimed to estimate the effectiveness of a community-based educational intervention in reducing the frequency of human cysticercosis in Burkina Faso. We did a cluster-randomised controlled trial between 2011 and 2014. 60 eligible villages from three provinces (Boulkiemdé, Sanguié, and Nayala) were randomly allocated to the intervention or control group. Villages raising pigs, that were not a regional capital or located on a main road, that were more than 20 km from Ouagadougou or 5 km from one another, were eligible. In each village, 60 participants were asked for blood samples at baseline, 18 months later (before randomisation), and 18 months after randomisation. Villages were block randomised (1:1) by pig-raising department immediately after the pre-randomisation visit. The intervention aimed to improve knowledge of Taenia solium transmission and control through screening and structured discussion of a 52-min movie, and to increase community self-efficacy through a Self-esteem, Associative strengths, Resourcefulness, Action planning, Responsibility (SARAR) approach via the Participatory Hygiene and Sanitation Transformation (PHAST) model. The primary outcome was active cysticercosis, defined as the presence of circulating antigens detected by use of B158/B60 ELISA. Effectiveness measured at the village level was estimated by use of three Bayesian hierarchical models. This study is registered with ClinicalTrials.gov, number NCT0309339. Two villages in the same randomisation block were excluded, resulting in a final sample size of 58 villages. Overall, the intervention tended towards a decrease in the cumulative incidence of active cysticercosis from baseline to after randomisation (adjusted cumulative incidence ratio 0·65, 95% Bayesian credible interval [95% CrI] 0·39-1·05) and a decrease in active cysticercosis prevalence from baseline to after randomisation (adjusted prevalence proportion ratio 0·84; 95% CrI 0·59-1·18). The intervention was shown to be effective in Nayala and Sanguié but not in Boulkiemdé. Community-engaged participatory interventions can be effective at reducing the incidence and prevalence of cysticercosis in some low-resource settings. US National Institutes of Health (National Institute of Neurological Disorders and Stroke, Fogarty International Center, and National Institute of General Medical Sciences).
Role of stereotactic body radiation therapy in patients with hepatocellular carcinoma extensively pretreated with transarterial chemoembolization or yttrium-90.
Authors: Kayo Tanimoto, Iris Rusu, Brendan Martin, Jennifer Price, Tarita Thomas
Journal: Journal of Clinical Oncology (2018)

233 Background: Hepatocellular carcinoma (HCC) is an aggressive disease with dismal outcomes. Patients who are not surgical candidates are routinely treated with local therapies such as TACE, Y90, or SRBT among others. The study aimed to assess treatment response and treatment related toxicity to SBRT in patients who received prior TACE or Y90 at our institution, some of whom subsequently underwent orthotopic liver transplantation. Methods: IRB approval was obtained to retrospectively review 26 medical records of patients who received SBRT at the Loyola University Medical Center from 9/9/14-12/28/16. GI toxicities were analyzed using the Common Terminology Criteria for Adverse Events (CTAE) version 4.0 following SBRT. Skin, pharyngeal/esophageal, thorax, lung, GU, and GI toxicities were included in toxicity analysis. Patients received radiation dose from 36 Gy - 50 Gy in 5 fractions using RTOG 1112 dose constraints for dosimetric plan evaluation. Fisher’s exact tests and Wilcoxon Rank Sum tests were used for statistical analysis. Results: Of the 26 patients, 21 patients had prior TACE (median 3 TACE procedures; ranging from 1-5). 6 patients had prior Y90 with or without prior TACE. Median follow up for the cohort was 51 weeks. No patient showed GI toxicities above grade 1 during SBRT, with fatigue and nausea being the most common. One patient who previously received Y90 developed fatal duodenal perforation. Pathology demonstrated this was related to tumor infiltration of the duodenum and was not related to post radiation necrosis. 6 patients went on to undergo OLT with all patients having treatment response on surgical pathology with 4 patients having complete treatment response. Conclusions: SBRT was shown to safely treat patients after prior therapies including Y90 and TACE. Furthermore, SBRT showed favorable outcomes in post-OLT patients. To our knowledge, this is the first study to assess the effects of SBRT following extensive local therapies for HCC including Y90. Prospective data is needed to evaluate these findings further with longer follow up.
NTDs Added to African Leaders Malaria Alliance Scorecard
Authors: M.J. Friedrich
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study
Authors: Philip Mease, Désirée van der Heijde, Robert Landewé, Shephard Mpofu, Proton Rahman, Hasan Tahir, Atul Singhal, Elke Boettcher, Sandra Navarra, Karin Meiser, Aimee Readie, Luminita Pricop, Ken Abrams
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Objectives</h3> To evaluate the effect of subcutaneous (s.c.) secukinumab, an interleukin-17A inhibitor, on clinical signs and symptoms and radiographic progression in patients with psoriatic arthritis (PsA). <h3>Methods</h3> Adults (n=996) with active PsA were randomised 2:2:2:3 to s.c. secukinumab 300 mg or 150 mg with loading dose (LD), 150 mg without LD or placebo. All groups received secukinumab or placebo at baseline, weeks 1, 2 and 3 and then every 4 weeks from week 4. The primary endpoint was the proportion of patients achieving an American College of Rheumatology 20 (ACR20) response at week 16. <h3>Results</h3> Significantly more patients achieved an ACR20 response at week 16 with secukinumab 300 mg with LD (62.6%), 150 mg with LD (55.5%) or 150 mg without LD (59.5%) than placebo (27.4%) (p&lt;0.0001 for all; non-responder imputation). Radiographic progression, as measured by van der Heijde-modified total Sharp score, was significantly inhibited at week 24 in all secukinumab arms versus placebo (p<i>&lt;</i>0.01 for 300 mg with LD and 150 mg without LD and p&lt;0.05 for 150 mg with LD; linear extrapolation). Adverse event rates at week 24 were similar across treatment arms: 63.1% (300 mg with LD), 62.7% (150 mg with LD), 61.1% (150 mg without LD) and 62.0% (placebo). No deaths or new safety signals were reported. <h3>Conclusion</h3> S.c. secukinumab 300 mg and 150 mg with and without LD significantly improved clinical signs and symptoms and inhibited radiographic structural progression versus placebo at week 24 in patients with PsA. <h3>Trial registration number</h3> NCT02404350; Results.
The Yet Unrealized Promise of Ovarian Cancer Screening
Authors: Charles W. Drescher, Garnet L. Anderson
Journal: JAMA Oncology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Using Microsoft PowerPoint, part 1
Authors: Mohammad Al-Ubaydli
Journal: BMJ (2004)

Content is king. MS PowerPoint has lots of power, but the points only come from you. Before you add exciting animations, colourful logos, and smooth transitions, think about what you are trying to tell your audience, and how best to tell them.

The main thing is to keep the main thing the main thing. Include a summary of your talk on one of your first …
THROMBOCYTOPENIA IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION WHO UNDERGO PERCUTANEOUS CORONARY INTERVENTION: INSIGHT FROM THE NATIONWIDE READMISSION DATABASE
Authors: Abel Casso Dominguez, Alejandro Lemor, Yasmin Herrera, Georges El Hayek, Chirag Bavishi, Ankit Chothani, Pedro Moreno
Journal: Journal of the American College of Cardiology (2018)
Abstract P4-12-13: Comparative analysis of costs between subcutaneous formulation of trastuzumab versus intravenous formulation from the perspective of the Instituto Oncológico Nacional of Panamá from January to December 2016
Authors: C Martin, J Alcedo, E Araúz
Journal: Cancer Research (2018)

Abstract Objective: Because there is actually availability of both Intravenous(IV) and subcutaneous(SC) formulation of Trastuzumab for use in the public sector in the Instituto Oncológico Nacional and knowing that de SC formulation has been compared previously with the IV in term of efficacy in and it was not inferior and also is prefered by patients it is useful to count with a study of costs minimization that can determine what formulation results more convenient to maintain available for use in the Instituto Oncológico Nacional based on the criteria of efficiency of the intervention.(1)(2) Methodology: This is a cost minimization study considering the cost of the treatment, the supplies and the time utilized by Pharmacy and Nursing to prepare and administer it. Results: In relation to the cost of the treatment the SC presentation has a cost per patient 17% less than the IV presentation in relation to the cost that offers the Pharmaceutical company, considering a weight of 70 kg per patient ( IV presentation) and a fixed dose of 600 mg(SC presentation). Considering the supplies utilized by Pharmacy and Nursing to prepare and administer the IV and SC presentation, the SC presentation requires less supplies and this facilitates its administration and decreases the cost of the treatement in a 67%. In terms of time invested in preparing and administering the IV and the SC formulation, accounting for both, nursing and pharmacy, it is observed that the SC formulation requires less amount of time than the IV formulation and this decreases the cost of the treatment in a 90%. Analisis of Saving by Use of SC Trastuzumab vs IV TrastuzumabItemSC TrastuzumabIV Trastuzumab% SavingTreatment10,578,0538,826,89417%Nursing Supplies18,9662,50387%Pharmacy Supplies31,98217,02047%Nursing Time71,7916,33591%Pharmacy Time2,28971669%Total anual cost10703081885346717% Conclusion: With the use of the SC formulation of Trastuzumab there is combined savings of 17%, that represents anually 5985 USD per patient based on a treatment of 18 cycles of Traztuzumab per year, that results in a total saving of 1,84 million USD per year. (1) Pivot et al. Lancet Oncol 2013 Sep;14(10):962-70. (2)Ismael G et al. Lancet Oncol 2012 Sep;13(9):869-78 Citation Format: Martin C, Alcedo J, Araúz E. Comparative analysis of costs between subcutaneous formulation of trastuzumab versus intravenous formulation from the perspective of the Instituto Oncológico Nacional of Panamá from January to December 2016 [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P4-12-13.
Abstract P3-06-06: Human endogenous retrovirus TROJAN promotes triple negative breast cancer progression and represents a potential therapeutic target
Authors: X Jin, X-E Xu, Y-Z Jiang, Z-M Shao
Journal: Cancer Research (2018)

Abstract Human endogenous retroviruses (HERVs) play pivotal roles in the development of breast cancer. However, the detailed mechanisms of noncoding HERVs remain elusive. We used RNA-Seq to analyze the transcription level of each HERV loci across the genome in eight pairs of triple negative breast cancer (TNBC) and normal breast tissues. We identified one LTR70, which we dubbed TROJAN, was a TNBC related HERV. We also found that HERVs could not be researched as families because each members from the same family had different expression patterns in TNBC. TROJAN promoted proliferation and invasion in TNBC cells and indicated poor outcomes in patients. Here, we confirmed that TROJAN regulated the progression of TNBC through multiple mechanisms, with ZMYND8, a metastasis-repressing factor, being one of the targets of TROJAN. TROJAN could bind to ZMYND8, promoting its degradation through ubiquitin-proteosome system, and downregulated the transcription level of EGFR, thus stimulating the metastasis of TNBC. The association of TROJAN, ZMYND8, and EGFR was subsequently confirmed in clinical samples. Furthermore, our study verified that the therapeutic delivery of antisense oligonucleotides targeting TROJAN significantly suppressed metastasis of TNBC in vivo. In conclusion, TROJAN promotes the progression of breast cancer and serves as a potential therapeutic target in TNBC. Citation Format: Jin X, Xu X-E, Jiang Y-Z, Shao Z-M. Human endogenous retrovirus TROJAN promotes triple negative breast cancer progression and represents a potential therapeutic target [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P3-06-06.
Severe Abdominal Pain With Hypotension
Authors: Amy Lynne Rosenbluth, Andrew Harrington, Eugenius John Harvey
Journal: JAMA Surgery (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
INTERLEUKIN-1 BETA IS ASSOCIATED WITH AORTIC VASCULAR INFLAMMATION ASSESSED BY 18-FDG PET/CT IN PATIENTS WITH PSORIASIS
Authors: Agastya Belur, Youssef Elnabawi, Amit Dey, Aparna Sajja, Aditya Goyal, Charlotte Harrington, Jacob Groenendyk, Heather Teague, Yvonne Baumer, Navya Nanda, Mark Ahlman, Aditya Joshi, Martin Playford, Nehal Mehta
Journal: Journal of the American College of Cardiology (2018)